Biocon - Stock Investment Idea | Monthly Pick

BIOCON is showing strong recovery, forming higher bottoms since March lows with rising volumes. It has broken trendline resistance, crossed above the 200 EMA, and formed a golden crossover. With RSI above 60 and price above the cloud, momentum looks strong. Accumulate in ₹355–₹365 zone for targets of ₹395–₹425. Stop loss: ₹334.

Expert recommendation by Mr. Arpan Shah (Head Technical Research)  (NISM-201600130194)

• Price: Rs 362
• Buying Price: Rs 355-365
• Target Price: Rs 395-425
• Stop loss: Rs 334
• Upside: 17%
• Time Frame: 10-12 Weeks

Stock Technical Analysis

• Stock witnessed sharp profit booking from the recent Swing high and made a low of 291 in March 2025. However; Stock has been making higher bottom formation on the daily chart since then along with volume activity
• Stock is trading above cloud and it has given a breakout from the trendline resistance zone
• Stock has also crossed above 200 days exponential moving average along with golden crossover (50 EMA crossing above 200 EMA)
• Momentum indicator RSI has given a breakout above 60 level on daily chart which indicates upside momentum is likely to continue in the coming days

Traders can look to accumulate BIOCON in the 355-365 zone and expect upside targets of 395-425 in 10-12 weeks with stoploss below 334 (closing basis).

Know more about Biocon Ltd.

India’s Pioneer in Biopharma, Building a Global Biosimilars Powerhouse

Biocon Ltd. is India’s flagship biopharmaceutical company and a global trailblazer in biosimilars, biologics, and research-driven specialty therapies. Founded in 1978 by Kiran Mazumdar-Shaw, Biocon has evolved from an enzyme manufacturer to a full-fledged innovation-led biopharma group with global ambitions and strategic partnerships.

Business Segments:

1. Biologics (via Biocon Biologics)
   1. One of the world’s few vertically integrated biosimilar companies
   2. Portfolio includes biosimilars for insulin, oncology, immunology, and more
   3. Strong pipeline and global commercial partnerships (including with Viatris, formerly Mylan)
2. Small Molecules
   1. High-quality APIs for statins, immunosuppressants, and anti-diabetics
   2. Supplies to leading generic companies worldwide
   3. Backward integration supports cost competitiveness
3. Branded Formulations (India + EMs)
   1. Focus on critical care, oncology, diabetes, and nephrology
   2. Strengthening presence in emerging markets beyond India
4. Syngene International Ltd. (Listed subsidiary)
   1. Leading CRO/CDMO partner to global pharma and biotech firms
   2. Adds scientific and monetizable R&D depth to Biocon's overall value proposition

Strategic Strengths for Investors:

• Global Biosimilar Leadership: Among the top contenders in the ~$100B biosimilar opportunity; insulin portfolio has global regulatory traction (FDA, EMA, etc.)
• Cost-Driven Innovation: R&D capabilities combined with Indian cost structures create high entry barriers for global peers
• Regulatory Credibility: Multiple USFDA/EU approvals position Biocon as a dependable global supplier
• ESG & Healthcare Access: Deep commitment to affordable biologics and access programs in low- and middle-income countries
• Growth Visibility: Biocon Biologics’ acquisition of Viatris’ biosimilar business offers direct control over front-end commercialization in advanced markets — a turning point in profitability and scale

For investors seeking long-term exposure to global healthcare trends — aging populations, chronic diseases, cost-sensitive biologics — Biocon is a unique India-origin, innovation-led story. With improving operating leverage, forward-integrated biosimilar distribution, and regulatory scale-up, Biocon stands at an inflection point to unlock value.

Website: www.biocon.com

Disclaimer - Investments in securities market are subject to market risk, read all the related document carefully before investing.          
https://www.mnclgroup.com/research-disclaimer